Chemotherapy Induced Neutropenia (CIN) Market Insight, Epidemiology and Market Forecast Report 2021-2030 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Chemotherapy Induced Neutropenia (CIN) Market Insight, Epidemiology and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.

This 'Chemotherapy Induced Neutropenia (CIN) Market Insights, Epidemiology, and Market Forecast-2030' report delivers an in-depth understanding of the CIN, historical and forecasted epidemiology as well as the CIN market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Chemotherapy Induced Neutropenia (CIN) Treatment

The management of CIN involves two main strategies: modification of the chemotherapy regimen and/or the use of growth factors. The optimal strategy for the management of CIN is prevention. In the management of CIN, myeloid growth factors (MGFs), including G-CSF and granulocyte macrophage-colony stimulating factor (GM-CSF), are used in clinical practice to reduce the risk of febrile neutropenia (FN) and its complications.

Currently, there are four recombinant G-CSF formulations: filgrastim (nonglycosylated), lenograstim (glycosylated), pegfilgrastim (filgrastim in pegylated version), and lipefilgrastim (filgrastim in glycosylate version). Biosimilar versions exist for filgrastim and pegfilgrastim. The pegylated version differs for the different plasma half-life, much longer than the non-pegylated version (3-4 h), and allows a single administration of the drug per chemotherapy cycle.

Chemotherapy Induced Neutropenia (CIN) Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by the Total number of patients on chemotherapy, Risk-specific chemotherapy patient pool for CIN, and Total incident cases of CIN by cancer type scenario in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.

Key Findings

• In the 7MM, the total estimated number of cancer patients on chemotherapy was 1,790,618 in 2020.
• In 2020, the highest number of cancer patients on chemotherapy were accounted by the US making up to 691,906, while the EU5 countries accounted for 778,973 number of cancer patients on chemotherapy. Japan ranked second among 7MM countries with 319,740 cancer patients on chemotherapy in 2020.
• Assessments as per the publisher show that there were 484,334 cases at intermediate-high risk for CIN, and 207,572 cases at low risk for CIN in the United States, in 2020.
• In 2020, the total number of cases of CIN in the 7MM was 903,597. The US accounted for a majority of cases in the 7MM with 383,339 cases.
• The CIN cases are included from various cancers such as breast, lung, ovarian, AML, lymphoma, and other cancers. Out of all cancers, in 2020, the highest CIN cases was from breast cancer i.e. 99,944 cases. Furthermore, 2,354 CIN cases in AML were the lowest among all cancers, in the US.
• Among the European countries, Germany had the highest cases of CIN with 96,877 cases, followed by the UK which had 78,494 cases of CIN in 2020. On the other hand, Spain had the lowest number of CIN cases in 2020, i.e. 46,167.
• In 2020, Japan accounted for 153,260 cases of CIN, which is second-highest after the US among 7MM countries.

Chemotherapy Induced Neutropenia (CIN) Market Outlook

United States contributes to the major share of the Chemotherapy Induced Neutropenia (CIN) market as compared to other 7MM countries.

The optimal strategy for the management of CIN is prevention. Neutropenia can be avoided or ameliorated by giving less chemotherapy or by stimulating marrow recovery as soon as possible after the chemotherapy, using the colony-stimulating factor (CSFs).

Treatment is required when neutropenia is associated with fever because the body may not be able to effectively fight an active infection that occurs during this time. Hospitalization is advisable for the majority of patients with FN. Broad-spectrum antibiotics are quickly initiated, and the patient is observed until the neutrophil count recovers. In the management of CIN, myeloid growth factors (MGFs), including G-CSF and granulocyte macrophage-colony stimulating factor (GM-CSF), are approved for clinical practice to reduce the FN risk and its complications.

Key Findings

• The therapeutic market of CIN in the 7MM was USD 5,128 million in 2020.
• The therapeutic market of CIN in the United States was USD 3,567 million in the year 2020.
• The current market of Chemotherapy Induced Neutropenia (CIN) is mainly covered by Neulasta, Neupogen, and their biosimilars. The market size of Neupogen and Neulasta was USD 216 million and USD 2,450 million, respectively in 2020.
• The market size in the 7MM might increase at a CAGR of 1.76%. An increase in the incidence of cancer, current and emerging chemotherapy treatment of cancer leading to neutropenia progression, are the primary factors driving the growth of the CIN market.
• The market size of Neupogen and Neulasta is expected to further decline due to the expected launch of new therapies and availability of biosimilars of both these therapies.
• Rolontis (Spectrum Pharmaceuticals), Plinabulin (BeyondSpring Pharmaceuticals), and F-627 (Evive Biotech) - pipeline candidates - are expected to enter the market in the forecasted period (2021-2030). Cosela (trilaciclib) is approved by the US FDA in February 2021.
• The therapeutic market of CIN in Japan was USD 504 million in the year 2020.

Key Topics Covered:

1 Key Insights

2 Report Introduction

3 Chemotherapy Induced Neutropenia (CIN) Market Overview at a Glance

4 Executive Summary of Chemotherapy Induced Neutropenia (CIN)

5 Disease Background and Overview

6 Treatment and Management

7 Epidemiology and Patient Population

8 Marketed Therapies

9 Emerging Therapies

10 Chemotherapy Induced Neutropenia (CIN): Seven Major Market Analysis

11 Market Outlook: 7MM

12 KOL Views

13 Market Drivers

14 Market Barriers

15 SWOT Analysis

16 Unmet Needs

17 Market Access and Reimbursement

18 Appendix

Companies Mentioned

• Amgen
• Kyowa Hakko Kirin Co., Ltd.
• Teva B.V.
• G1 Therapeutics
• Spectrum Pharmaceuticals
• Enzychem Lifesciences Corporation
• Aileron Therapeutics
• Cellerant Therapeutics
• Myelo therapeutics
• BeyondSpring Pharmaceuticals
• Evive Biotech

For more information about this report visit https://www.researchandmarkets.com/r/6x586d